Martin Capital Partners LLC Buys New Holdings in Novo Nordisk A/S (NYSE:NVO)

Martin Capital Partners LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 21,150 shares of the company's stock, valued at approximately $1,469,000.

A number of other institutional investors have also recently made changes to their positions in NVO. Center for Financial Planning Inc. boosted its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S in the 4th quarter worth about $29,000. Transce3nd LLC bought a new position in Novo Nordisk A/S in the 4th quarter worth about $33,000. Finally, CX Institutional bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $36,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NYSE:NVO traded down $1.15 during mid-day trading on Friday, reaching $79.90. The stock had a trading volume of 7,465,072 shares, compared to its average volume of 7,008,958. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a 50 day moving average price of $66.93 and a two-hundred day moving average price of $80.00. The stock has a market capitalization of $358.57 billion, a P/E ratio of 24.29, a P/E/G ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. As a group, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NVO shares. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.